Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Who can join

• Are 18 to 75 years old.
• Have AML that meets the study’s diagnosis rules, but not acute promyelocytic leukemia, a type of AML.
• Have medium- or high-risk AML in first remission, or AML of any risk in second remission. Remission means signs of cancer have gone away; blood counts do not need to be fully back to normal.
• Plan to get a stem cell transplant from a related or unrelated donor with no more than one tissue-marker mismatch, or from a half-matched donor using stem cells collected from blood.
• Plan to receive treatment to prepare for transplant with a Transplant Conditioning Score of at least 1.5.
• Plan to use tacrolimus (TAC) to help prevent graft-versus-host disease, when donor cells attack your body.
• Are fully active, or can walk and do light work but cannot do heavy physical activity.

Who can't join

• Use cyclosporine (CsA), anti-thymocyte globulin (ATG), alemtuzumab, or abatacept to prevent donor cells from attacking your body.
• Have or have ever had macular edema, swelling in the part of the eye used for sharp central vision.
• Have heart, lung, liver, or kidney function problems.
• Have liver blood tests called AST or ALT above 2.5 times the upper normal limit, or total bilirubin above 1.5 mg/dL.
• Have an estimated kidney filtering rate, called creatinine clearance, below 45 mL/min using the study’s calculation.
• Have diabetes.
• Have or have ever had uveitis, inflammation inside the eye.